Figure 3
Figure 3. BCL6 represses PTPROt via direct interactions with the PTPROt promoter region. (A) BCL6 binds to the PTPROt promoter in vivo. Chromatin immunoprecipitation was performed in 2 DLBCL cell lines (DHL4 and DHL6) using BCL6 antibody or normal IgG as control. The target amplicons in the PTPROt promoter include the 3 predicted BCL6 binding sites (BS1-3, ■) and 2 distant upstream or downstream control regions (C1 and C2, □). The BCL6 versus IgG ratio was calculated for each region and normalized to control region 1. (B) BCL6-mediated repression of PTPROt promoter requires intact BCL6 binding sites. PTPROt-promoter-driven luciferase constructs with or without the individual or combined mutations in the predicted BCL6 binding sites were cotransfected with pMT2T-HA-BCL6 into HEK293T cells. Luciferase activities were determined thereafter.

BCL6 represses PTPROt via direct interactions with the PTPROt promoter region. (A) BCL6 binds to the PTPROt promoter in vivo. Chromatin immunoprecipitation was performed in 2 DLBCL cell lines (DHL4 and DHL6) using BCL6 antibody or normal IgG as control. The target amplicons in the PTPROt promoter include the 3 predicted BCL6 binding sites (BS1-3, ■) and 2 distant upstream or downstream control regions (C1 and C2, □). The BCL6 versus IgG ratio was calculated for each region and normalized to control region 1. (B) BCL6-mediated repression of PTPROt promoter requires intact BCL6 binding sites. PTPROt-promoter-driven luciferase constructs with or without the individual or combined mutations in the predicted BCL6 binding sites were cotransfected with pMT2T-HA-BCL6 into HEK293T cells. Luciferase activities were determined thereafter.

Close Modal

or Create an Account

Close Modal
Close Modal